| Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial HJL Heerspink, J Radhakrishnan, CE Alpers, J Barratt, S Bieler, U Diva, ... The Lancet 401 (10388), 1584-1594, 2023 | 98 | 2023 |
| Gestational diabetes mellitus alone in the absence of subsequent diabetes is associated with microalbuminuria: results from the Kidney Early Evaluation Program (KEEP) AS Bomback, Y Rekhtman, AT Whaley-Connell, AV Kshirsagar, ... Diabetes care 33 (12), 2586-2591, 2010 | 58 | 2010 |
| Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren+ valsartan) therapy AS Bomback, Y Rekhtman, PJ Klemmer, PA Canetta, J Radhakrishnan, ... Journal of the American Society of Hypertension 6 (5), 338-345, 2012 | 49 | 2012 |
| Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial BH Rovin, J Barratt, HJL Heerspink, CE Alpers, S Bieler, DW Chae, ... The Lancet 402 (10417), 2077-2090, 2023 | 47 | 2023 |
| Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport syndrome X Liu, GM Ducasa, SK Mallela, JJ Kim, J Molina, A Mitrofanova, ... Kidney international 98 (5), 1275-1285, 2020 | 42 | 2020 |
| Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation DS Tsapepas, R Vasilescu, B Tanriover, Y Coppleson, Y Rekhtman, ... Transplantation 97 (6), 642-647, 2014 | 37 | 2014 |
| Novel therapies for Alport syndrome E Chavez, J Rodriguez, Y Drexler, A Fornoni Frontiers in medicine 9, 848389, 2022 | 35 | 2022 |
| Definition, identification and treatment of resistant hypertension in chronic kidney disease patients YR Drexler, AS Bomback Nephrology Dialysis Transplantation 29 (7), 1327-1335, 2014 | 33 | 2014 |
| Sphingosine-1-phosphate metabolism and signaling in kidney diseases Y Drexler, J Molina, A Mitrofanova, A Fornoni, S Merscher Journal of the American Society of Nephrology 32 (1), 9-31, 2021 | 31 | 2021 |
| Aldosterone blockade in chronic kidney disease JS Hirsch, Y Drexler, AS Bomback Seminars in nephrology 34 (3), 307-322, 2014 | 27 | 2014 |
| Role of sphingolipid signaling in glomerular diseases: focus on DKD and FSGS A Mitrofanova, Y Drexler, S Merscher, A Fornoni Journal of cellular signaling 1 (3), 56, 2020 | 18 | 2020 |
| Associations of sodium and potassium intake with chronic kidney disease in a prospective cohort study: findings from the Hispanic Community Health Study/Study of Latinos, 2008–2017 SL Swift, Y Drexler, D Sotres-Alvarez, L Raij, MM Llabre, N Schneiderman, ... BMC nephrology 23 (1), 133, 2022 | 15 | 2022 |
| Renal transplantation in familial dysautonomia: report of two cases and review of the literature Y Rekhtman, AS Bomback, MA Nash, SD Cohen, A Matalon, DM Jan, ... Clinical Journal of the American Society of Nephrology 5 (9), 1676-1680, 2010 | 15 | 2010 |
| The Case∣ Metabolic alkalosis in a patient with cystic fibrosis AS Geara, A Parikh, Y Rekhtman, MK Rao Kidney international 81 (4), 421-422, 2012 | 10 | 2012 |
| Management of lupus nephritis: new treatments and updated guidelines R Avasare, Y Drexler, DJ Caster, A Mitrofanova, JA Jefferson Kidney360 4 (10), 1503-1511, 2023 | 9 | 2023 |
| In vitro atrial septal ablation using high-intensity focused ultrasound Y Takei, R Muratore, A Kalisz, K Okajima, K Fujimoto, T Hasegawa, K Arai, ... Journal of the American Society of Echocardiography 25 (4), 467-472, 2012 | 9 | 2012 |
| Retrospective analysis of the impact of severe obesity on kidney transplant outcomes D Tsapepas, V Sandra, LA Dale, Y Drexler, KL King, M Yu, K Toma, ... Nephrology Dialysis Transplantation 38 (2), 472-480, 2023 | 7 | 2023 |
| Age of onset and disease course in biopsy-proven minimal change disease: an analysis from the cure glomerulonephropathy network DP Chen, ME Helmuth, AR Smith, PA Canetta, I Ayoub, K Mucha, ... American Journal of Kidney Diseases 81 (6), 695-706. e1, 2023 | 4 | 2023 |
| Identification of glomerular and plasma apolipoprotein M as novel biomarkers in glomerular disease Y Drexler, J Molina, T Elfassy, R Ma, C Christoffersen, M Kurano, ... Kidney International Reports 8 (4), 884-897, 2023 | 4 | 2023 |
| Mineralocorticoid receptor-associated hypertension and target organ damage: clinical relevance for resistant hypertension in end stage renal disease Y Rekhtman, A S Bomback Current Hypertension Reviews 8 (4), 267-275, 2012 | 4 | 2012 |
